CCL Oct 2017 - The Cancer Letter

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Request Cancellation

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Researchers confirm IASLC proposed characterization of uncertain R Status R(un), prognosis between R0 and R1

Trastuzumab for HER-2-expressing tumors needn't delay breast reconstruction

Local radiation provides comparable control of brain metastases compared to surgery

Cleveland Clinic study: timing of melanoma diagnosis, treatment critical to survival

Pfizer, Astellas report positive results from trial of Xtandi in non-metastatic castration-resistant disease

Argos Therapeutics reports interim analysis of phase III ADAPT trial

NCI CTEP-Approved Trials for October

FDA approves Kite's CAR-T cell therapy; another win for NCI's intramural program

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login